PerkinElmer has introduced ready-to-use Adeno-associated Virus Vectors (AAV) detection kits to help accelerate gene therapy research.

The new detection kits are intended to help researchers who are working to develop gene therapies for various serious diseases.

They help with the characterisation of viral vector particles that are being produced to enable gene transfer decision-making.

PerkinElmer has used its AlphaLISA technology for the development of the fully automatable and validated assays. The technology also does not require separation.

The viral vector assays are said to be the only optimised, no-wash AAV detection assays presently available on the market.

PerkinElmer stated that the latest offering will expand the options available for researchers to measure viral concentrations. Currently, ELISA and other wash-based systems can be time-consuming with limited ranges.

The new high-throughput viral assays are designed with an easier-to-use, high-throughput process to streamline gene therapy research as well as development workflows.

Perkinelmer Life Sciences senior vice-president Dr Alan Fletcher said: “One of the best ways to support gene therapy researchers is to provide solutions to help them navigate the unique workflows they work with to shorten and simplify the path from lab to clinic.

“Our new AAV detection kits are designed to do that by eliminating long, tedious protocols while expanding the detection range to enable potential cures for people living with cancer, Alzheimer’s, muscular dystrophy, infectious diseases and more.”

The AlphaLISA AAV detection kits support different serotypes, including AAV1, AAV2, AAV3B, AAV5, AAV6, AAV8 and AAV9.

They provide a broad detection range for viral titer measurements in a no-wash format, using bead-based luminescent amplification. They can also be miniaturised to support 384 and 1,536 well plate throughput.

Each of the seven kits is designed for detecting specific serotypes to target various cell types in the body for gene therapy application.